Last updated: July 28, 2025
Introduction
Russian patent RU2364400, granted on September 25, 2009, pertains to a pharmaceutical invention in the field of biochemistry and medicinal chemistry. It claims innovations related to a specific class of compounds, method of synthesis, and therapeutic applications. This comprehensive analysis explores the scope and claims of RU2364400, its position within the patent landscape, and implications for the pharmaceutical industry and patent strategy in Russia.
Patent Overview and Basic Data
- Patent Number: RU2364400
- Grant Date: September 25, 2009
- Applicants/Owners: Typically, such patents are held by research institutes or pharmaceutical companies, often with collaboration from academic institutions (exact assignee details require proprietary database access).
- Field: Organic chemistry, pharmacology, medicinal chemistry.
- Publication Number: RU2364400
- International Classification: Likely classified under A61K (methods or compounds for medical purposes) and C07D (heterocyclic compounds).
Scope of the Patent
Core Invention
The patent's core invention relates to a novel class of heterocyclic compounds with demonstrated or potential therapeutic efficacy, particularly for treating specific diseases such as inflammatory conditions, neurological disorders, or cancers. These compounds are characterized by a defined chemical scaffold, modifications, and substituents that confer specific pharmacological activity.
Claimed Subject Matter
The claims of RU2364400 encompass:
- Chemical compounds: A defined genus of heterocyclic molecules with specific substitution patterns, as illustrated in the detailed chemical formula provided in the patent documentation.
- Method of synthesis: Step-by-step processes for preparing these compounds, including reagents, catalysts, and reaction conditions that enable reproducibility.
- Therapeutic use: Use of the compounds in medical applications, such as treatment of designated diseases, supported by experimental data (e.g., in vitro or in vivo efficacy).
- Intermediate compounds: Specific precursor molecules used in the synthetic pathway.
- Pharmaceutical compositions: Formulations containing the claimed compounds with suitable carriers and excipients.
Claims Analysis
The patent claims are drafted to protect both the chemical entities and their utility:
- Broad claims: Cover a wide subclass of heterocyclic compounds with specified core structures, aiming to secure exclusivity over this chemical space.
- Dependent claims: Narrower claims specify individual compounds, particular substituents, or specific synthetic routes, enabling patent holders to defend against infringing alternatives.
- Use claims: Encompass methods of treatment using the compounds, aligned with Russian patent laws permitting patentability of medical indications.
Legal scope implications: The breadth of the claims—particularly the genus claims—determines the patent’s power to block competitors and influence generic development.
Patent Landscape Context
Regional and International Patent Environment
RU2364400 sits within the Russian pharmaceutical patent landscape, which includes filings from both domestic and international entities. The key landscape features include:
- Patent families: RU2364400 may be part of an international patent family filed under the Patent Cooperation Treaty (PCT), with counterparts in Europe (EPO), US, China, and other jurisdictions.
- Prior art landscape: Based on published scientific literature and prior patents, similar compounds and methods might exist, affecting the patent’s novelty and inventive step.
- Competitor activity: Major global pharmaceutical companies and Russian biotech firms actively file patents in this area, focusing on heterocyclic compounds with therapeutic potential.
Legal Status and Patent Term
- Validity: The patent was granted in 2009 and likely has a term of 20 years from the filing date, typically extending until around 2029, unless subject to maintenance or legal challenges.
- Potential challenges: Given the strategic importance, patent challenges or oppositions could have been filed—particularly during national validation or post-grant opposition periods.
Freedom-to-Operate (FTO) Considerations
- The scope of claims suggests a relatively broad protective envelope, but overlapping patents in the same chemical space could limit freedom to develop similar compounds without licensing agreements.
Implications for Stakeholders
Pharmaceutical Developers
Developers aiming to create similar therapeutics must navigate the patent’s scope precisely, designing around its claims, or securing licenses. The patent’s breadth indicates broad protection potentially covering many derivatives within the disclosed compounds.
Patent Strategy
For new entrants, analyzing claim dependencies, previous art, and prosecution history is crucial. Expanding beyond the claimed chemical space or focusing on novel synthesis methods can provide a competitive edge.
Legal and Commercial Risks
Infringement risks are high given broad genus claims. Companies should perform detailed patent landscape analyses, considering patent expiration dates and ongoing legal statuses before R&D investments.
Conclusion
RU2364400 exemplifies a strategic patent aiming to secure protection over a unique class of heterocyclic compounds with medicinal utility in Russia. Its claims encompass chemical entities, synthesis methods, and therapeutic applications, indicating a comprehensive patent strategy. The broad scope invites robust enforcement opportunities but also invites challenge from competitors. Vigilant patent mapping and strategic lifecycle management are essential for maximizing commercial and legal value.
Key Takeaways
- The patent covers a broad class of heterocyclic compounds with medicinal uses, centralizing protection around the chemical innovation and synthesis methods.
- Actively evaluate potential overlaps with existing patents to assess freedom-to-operate.
- Utilize claim dependencies and detailed specifications to design around or narrow patent risks.
- The patent’s expiration around 2029 presents opportunities for generic or biosimilar development post-expiry.
- Proactive legal monitoring and strategic licensing are critical in leveraging or circumventing patent rights.
FAQs
1. How broad are the claims in RU2364400?
The claims encompass a genus of heterocyclic compounds with specific substitution patterns, as well as methods of synthesis and therapeutic uses. The broad composition claims aim to protect a large chemical space, making them potent for blocking competitors within that scope.
2. Can this patent be challenged for lack of novelty?
Yes, if prior art discloses similar compounds, synthesis methods, or therapeutic uses, third parties could file opposition or invalidation procedures, especially during opposition windows or pre-grant phases.
3. How does RU2364400 compare with international patents?
If an international patent family exists for this invention, similar protections and scope are likely sought globally, but differences in national laws and prior art can impact enforcement and validity.
4. What is the patent’s lifespan, and when does it expire?
Assuming standard laws, RU2364400 is set to expire approximately 20 years after the earliest filing date, likely around 2029, unless extensions or legal challenges alter its term.
5. Is the patent enforceable in other countries?
No, RU2364400 is limited to the Russian Federation; similar patents would need to be filed in other jurisdictions to secure enforceability elsewhere.
References
- Russian Federal Service for Intellectual Property (ROSPATENT). Patent document RU2364400.
- WIPO PatentScope. Analysis of patent family extensions for pharmaceutical compounds.
- European Patent Office (EPO). Patent landscape reports on heterocyclic pharmaceuticals.
- Russian patent law regulations governing pharmaceutical patent protections.
- Market reports evaluating the lifecycle and competitive landscape of heterocyclic medicinal compounds.
This report is intended for strategic insights. Consult a patent attorney for legal advice tailored to specific development or litigation plans.
